Therapy Areas: AIDS & HIV
Viriom starts the first phase one clinical trial of HIV treatment VM1500A
21 December 2018 -

United States-based Viriom Inc announced yesterday that it has started the first phase one clinical trial of the long-acting nanoformulation of VM1500A in HIV-uninfected volunteers, it was reported yesterday.

This trial is designed to assess the safety and pharmacokinetics of VM1500A once monthly dosing in up to 36 HIV-uninfected volunteers in a single site clinical trial in Moscow, Russia. Animal studies of VM1500A long acting injectable (VM-1500A-LAI) have indicated an excellent pharmacokinetic profile suggesting feasibility of once monthly or once quarterly dosing to achieve effective antiviral target exposure.

The company is assessing intramuscular and subcutaneous injectable formulations of VM-1500A-LAI.

Login
Username:

Password: